Citations 29

Psychological distress in Rome III functional dyspepsia patients presenting for testing of gastric emptying

Neurogastroenterology & Motility | October 29, 2015 | Volume: 28 | Issue: 2 | Pages: 196-205

10.1111/nmo.12709 | PMID 26511077

AbstractBackgroundThere have been conflicting results from studies that have evaluated psychological disturbances in functional dyspepsia (FD). We conducted a comprehensive survey of psychological measures in patients undergoing gastric emptying testing (GET) in order to determine the relationship among psychological distress, gastric emptying, and dyspeptic symptoms.MethodsConsecutive patients referred for GET were prospectively enrolled. Details regarding patient characteristics, health care utilization, dyspeptic symptoms, quality of life, and psychological dysfunction were obtained. Depression, anxiety, somatization, stress, positive and negative affect, and alexithymia were queried using validated questionnaires. We compared those dyspeptic patients who met Rome III criteria for FD to those who did not meet these criteria.Key ResultsTwo hundred and nine patients (160 female; mean age 46.6 years ± 17.3 years) participated. Around 151 patients (72%) met Rome III criteria for FD. In the entire group, a high level of depression, anxiety, somatization, and perceived stress was present compared to population norms. Health care seeking behavior and symptom severity were greater in those with FD and quality of life was lower compared to non‐FD. Gastric emptying did not differentiate the two groups and similar degrees of psychological distress were present whether emptying was delayed or normal.Conclusions & InferencesIn patients referred for GET, substantial psychological distress is present. The degree of distress was similar regardless of whether the patient met Rome III FD criteria or not. Further evaluation of psychological dysfunction in FD patients may lead to improved diagnosis and determination of the most appropriate treatment.
The impact of obesity on oesophageal acid exposure time on and off proton pump inhibitor therapy

Alimentary Pharmacology & Therapeutics | September 8, 2015 | Volume: 42 | Issue: 9 | Pages: 1093-1100

10.1111/apt.13394 | PMID 26345151

SummaryBackgroundObesity is associated with increased oesophageal acid exposure time (AET) in patients with gastro‐oesophageal reflux (GER), and may decrease the effects of proton pump inhibitors (PPIs).AimTo evaluate the effects of increased body mass on the ability of PPI therapy to decrease AET in patients with reflux symptoms.MethodsAcid exposure time profiles collected from adult patients using wireless pH‐metry while on or off PPI therapy was retrospectively reviewed. Patients were separated into five body mass index (BMI) categories as defined by the World Health Organization. A multivariable logistic regression evaluated the association between abnormal AET and BMI groups while controlling for age, gender and pH capsule placement methods.ResultsThe study group comprised 968 patients with 336 (34.7%) studied on a PPI and 632 (65.3%) studied off PPI therapy. AET (total greater than 5.3%) was found more frequently in the overweight (67%) and obese classes (74–80%) compared to those who were normal weight (40%) while off acid‐suppressing medications (P < 0.001). No significant differences were found between these groups when studied on acid‐suppressing medications, and the proportion of patients with abnormal AET across BMI classes was similar regardless of taking a PPI either once or twice daily.ConclusionsThis is the largest study to report on the relationship between BMI and oesophageal acid exposure time in patients with GER on and off PPI therapy. We conclude that obesity is related to increased acid exposure time, but with no significant difference in acid exposure time among different weight‐based groups when taking a once or twice‐daily PPI.
The Impact of Pelvic Floor and Lower Gastrointestinal Symptoms on Quality of Life in Women With Systemic Sclerosis

Journal of Clinical Gastroenterology | September 1, 2015 | Volume: 50 | Issue: 6 | Pages: e55-e59

10.1097/mcg.0000000000000405 | PMID 26325189

Background: Systemic sclerosis (SSc) patients with gastrointestinal (GI) involvement have a lower quality of life (QoL) and while the impact of upper GI symptoms on QoL in SSc patients has been described few data exist on the presence and impact of lower gastrointestinal (LGI) and pelvic floor symptoms in SSc. Our goal was to assess the prevalence of these symptoms in women with SSc and evaluate their impact on QoL. A secondary hypothesis was that the impact of LGI symptoms on QoL is mediated by depression. Study: Women with SSc (n=175) attending an outpatient scleroderma clinic completed multiple validated questionnaires. Pelvic floor and LGI symptoms included fecal incontinence (FI), urinary incontinence (UI), dual incontinence (DI), chronic constipation, diarrhea, and pelvic pain. The Student t tests adjusted for multiple comparisons were used to evaluate group differences at the 0.05 level. Results: Complete data were available for 160 women. FI was reported by 65, UI by 64, DI by 40, chronic constipation by 94, diarrhea by 82, and pelvic pain by 35 of SSc patients. Overall QoL was reduced in SSc patients with FI (0.96 vs. 0.63; P=0.007), UI (0.96 vs. 0.65; P=0.01), DI (1.11 vs. 0.67; P=0.002), and pelvic pain (1.01 vs. 0.70; P=0.04). Antidepressant use was reported by 26%. The negative impact on QoL in patients with pelvic floor symptoms was partially mediated by depression. Conclusions: Women with SSc suffer from an increased prevalence of LGI and pelvic floor symptoms including FI, UI, diarrhea, constipation, and pelvic pain and this effect seems to be partially mediated by depression.
Faculty Opinions recommendation of Weight and type 2 diabetes after bariatric surgery: systematic review and meta-analysis.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature | September 17, 2012 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.3410/f.717955916.793460838

Faculty Opinions recommendation of The clinical effectiveness and cost-effectiveness of surgery for people with morbid obesity: a systematic review and economic evaluation.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature | September 17, 2012 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.3410/f.717955913.793460835

Faculty Opinions recommendation of Lifestyle, diabetes, and cardiovascular risk factors 10 years after bariatric surgery.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature | September 17, 2012 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.3410/f.717955794.793460816

Faculty Opinions recommendation of Risk assessment in cholelithiasis: is cholecystectomy always to be preferred?

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature | August 21, 2012 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.3410/f.4342956.4165054

Review article: current treatment options and management of functional dyspepsia

Alimentary Pharmacology & Therapeutics | May 17, 2012 | Volume: 36 | Issue: 1 | Pages: 3-15

10.1111/j.1365-2036.2012.05128.x | PMID 22591037

SummaryBackgroundFunctional dyspepsia (FD), a common functional gastrointestinal disorder, is defined by the Rome III criteria as symptoms of epigastric pain or discomfort (prevalence in FD of 89–90%), postprandial fullness (75–88%), and early satiety (50–82%) within the last 3 months with symptom onset at least 6 months earlier. Patients cannot have any evidence of structural disease to explain symptoms and predominant symptoms of gastroesophageal reflux are exclusionary. Symptoms of FD are non‐specific and the pathophysiology is diverse, which explains in part why a universally effective treatment for FD remains elusive.AimTo present current management options for the treatment of FD (therapeutic gain/response rate noted when available).ResultsThe utility of Helicobacter pylori eradication for the treatment of FD is modest (6–14% therapeutic gain), while the therapeutic efficacy of proton pump inhibitors (PPI) (7–10% therapeutic gain), histamine‐type‐2‐receptor antagonists (8–35% therapeutic gain), prokinetic agents (18–45%), tricyclic antidepressants (TCA) (response rates of 64–70%), serotonin reuptake inhibitors (no better than placebo) is limited and hampered by inadequate data. This review discusses dietary interventions and analyses studies involving complementary and alternative medications, and psychological therapies.ConclusionsA reasonable treatment approach based on current evidence is to initiate therapy with a daily PPI in H. pylori‐negative FD patients. If symptoms persist, a therapeutic trial with a tricyclic antidepressant may be initiated. If symptoms continue, the clinician can possibly initiate therapy with an anti‐nociceptive agent, a prokinetic agent, or some form of complementary and alternative medications, although evidence from prospective studies to support this approach is limited.
Human gut microbiota in obesity and after gastric bypass

Proceedings of the National Academy of Sciences | January 21, 2009 | Volume: 106 | Issue: 7 | Pages: 2365-2370

10.1073/pnas.0812600106 | PMID 19164560

Recent evidence suggests that the microbial community in the human intestine may play an important role in the pathogenesis of obesity. We examined 184,094 sequences of microbial 16S rRNA genes from PCR amplicons by using the 454 pyrosequencing technology to compare the microbial community structures of 9 individuals, 3 in each of the categories of normal weight, morbidly obese, and post-gastric-bypass surgery. Phylogenetic analysis demonstrated that although the Bacteria in the human intestinal community were highly diverse, they fell mainly into 6 bacterial divisions that had distinct differences in the 3 study groups. Specifically, Firmicutes were dominant in normal-weight and obese individuals but significantly decreased in post-gastric-bypass individuals, who had a proportional increase of Gammaproteobacteria . Numbers of the H 2 -producing Prevotellaceae were highly enriched in the obese individuals. Unlike the highly diverse Bacteria , the Archaea comprised mainly members of the order Methanobacteriales , which are H 2 -oxidizing methanogens. Using real-time PCR, we detected significantly higher numbers of H 2 -utilizing methanogenic Archaea in obese individuals than in normal-weight or post-gastric-bypass individuals. The coexistence of H 2 -producing bacteria with relatively high numbers of H 2 -utilizing methanogenic Archaea in the gastrointestinal tract of obese individuals leads to the hypothesis that interspecies H 2 transfer between bacterial and archaeal species is an important mechanism for increasing energy uptake by the human large intestine in obese persons. The large bacterial population shift seen in the post-gastric-bypass individuals may reflect the double impact of the gut alteration caused by the surgical procedure and the consequent changes in food ingestion and digestion.